Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:SCLN's Cash-to-Debt is ranked higher than
99% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:SCLN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SCLN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.90
NAS:SCLN's Equity-to-Asset is ranked higher than
92% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:SCLN: 0.90 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SCLN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.84 Max: 0.97
Current: 0.9
0.52
0.97
Interest Coverage No Debt
NAS:SCLN's Interest Coverage is ranked higher than
98% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. NAS:SCLN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:SCLN' s Interest Coverage Range Over the Past 10 Years
Min: 34.65  Med: 125.39 Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 14.33
Beneish M-Score: -2.17
WACC vs ROIC
9.89%
49.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 25.82
NAS:SCLN's Operating Margin % is ranked higher than
90% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NAS:SCLN: 25.82 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SCLN' s Operating Margin % Range Over the Past 10 Years
Min: -30.48  Med: 18.21 Max: 26.31
Current: 25.82
-30.48
26.31
Net Margin % 25.18
NAS:SCLN's Net Margin % is ranked higher than
91% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. NAS:SCLN: 25.18 )
Ranked among companies with meaningful Net Margin % only.
NAS:SCLN' s Net Margin % Range Over the Past 10 Years
Min: -26.84  Med: 17.6 Max: 25.18
Current: 25.18
-26.84
25.18
ROE % 19.68
NAS:SCLN's ROE % is ranked higher than
84% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. NAS:SCLN: 19.68 )
Ranked among companies with meaningful ROE % only.
NAS:SCLN' s ROE % Range Over the Past 10 Years
Min: -19.53  Med: 16.13 Max: 30.21
Current: 19.68
-19.53
30.21
ROA % 17.74
NAS:SCLN's ROA % is ranked higher than
92% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NAS:SCLN: 17.74 )
Ranked among companies with meaningful ROA % only.
NAS:SCLN' s ROA % Range Over the Past 10 Years
Min: -16.41  Med: 13.67 Max: 25.6
Current: 17.74
-16.41
25.6
ROC (Joel Greenblatt) % 114.12
NAS:SCLN's ROC (Joel Greenblatt) % is ranked higher than
96% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. NAS:SCLN: 114.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SCLN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -85.76  Med: 78.93 Max: 114.12
Current: 114.12
-85.76
114.12
3-Year Revenue Growth Rate 9.60
NAS:SCLN's 3-Year Revenue Growth Rate is ranked higher than
64% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NAS:SCLN: 9.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SCLN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -47.3  Med: 15.3 Max: 182.3
Current: 9.6
-47.3
182.3
3-Year EBITDA Growth Rate 36.10
NAS:SCLN's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NAS:SCLN: 36.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SCLN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.9  Med: -1.7 Max: 73.6
Current: 36.1
-53.9
73.6
3-Year EPS without NRI Growth Rate 42.60
NAS:SCLN's 3-Year EPS without NRI Growth Rate is ranked higher than
86% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NAS:SCLN: 42.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SCLN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -58.7  Med: 1.9 Max: 132.1
Current: 42.6
-58.7
132.1
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SCLN's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SCLN Guru Trades in Q3 2016

Jim Simons 1,385,000 sh (+19.22%)
Ken Fisher 222,827 sh (-25.23%)
» More
Q4 2016

SCLN Guru Trades in Q4 2016

Jim Simons 1,769,898 sh (+27.79%)
Ken Fisher 116,217 sh (-47.84%)
» More
Q1 2017

SCLN Guru Trades in Q1 2017

Paul Tudor Jones 32,200 sh (New)
Ken Fisher 155,623 sh (+33.91%)
Jim Simons 2,084,100 sh (+17.75%)
» More
Q2 2017

SCLN Guru Trades in Q2 2017

Ken Fisher 226,335 sh (+45.44%)
Jim Simons 2,540,200 sh (+21.88%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SCLN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 45.44%$9.3 - $10.98 $ 11.1512%226,335
Ken Fisher 2017-03-31 Add 33.91%$9.4 - $10.85 $ 11.1512%155,623
Ken Fisher 2016-12-31 Reduce -47.84%$8.65 - $10.8 $ 11.1512%116,217
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:ROCO:6550, NAS:SGYP, XKRX:170900, SHSE:600781, SZSE:300519, SZSE:002826, HKSE:01558, SZSE:002728, NAS:SCMP, CAI:PHAR, ISX:INAF, XKRX:000640, ISX:SIDO, SHSE:603520, XKRX:237690, ROCO:4123, TSE:3341, NAS:KPTI, SZSE:000790, HKSE:00932 » details
Traded in other countries:SPJ.Germany,
Headquarter Location:USA
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.

SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.

Ratios

vs
industry
vs
history
PE Ratio 13.60
SCLN's PE Ratio is ranked higher than
82% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. SCLN: 13.60 )
Ranked among companies with meaningful PE Ratio only.
SCLN' s PE Ratio Range Over the Past 10 Years
Min: 6.32  Med: 15.68 Max: 161
Current: 13.6
6.32
161
PE Ratio without NRI 13.60
SCLN's PE Ratio without NRI is ranked higher than
83% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. SCLN: 13.60 )
Ranked among companies with meaningful PE Ratio without NRI only.
SCLN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.32  Med: 15.68 Max: 161
Current: 13.6
6.32
161
Price-to-Owner-Earnings 21.95
SCLN's Price-to-Owner-Earnings is ranked higher than
69% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. SCLN: 21.95 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SCLN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.4  Med: 18.96 Max: 83.89
Current: 21.95
6.4
83.89
PB Ratio 2.33
SCLN's PB Ratio is ranked higher than
58% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. SCLN: 2.33 )
Ranked among companies with meaningful PB Ratio only.
SCLN' s PB Ratio Range Over the Past 10 Years
Min: 0.82  Med: 2.18 Max: 4.31
Current: 2.33
0.82
4.31
PS Ratio 3.43
SCLN's PS Ratio is ranked lower than
56% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. SCLN: 3.43 )
Ranked among companies with meaningful PS Ratio only.
SCLN' s PS Ratio Range Over the Past 10 Years
Min: 0.67  Med: 2.41 Max: 4.53
Current: 3.43
0.67
4.53
Price-to-Free-Cash-Flow 17.13
SCLN's Price-to-Free-Cash-Flow is ranked higher than
67% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. SCLN: 17.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SCLN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.85  Med: 15.87 Max: 458
Current: 17.13
3.85
458
Price-to-Operating-Cash-Flow 16.52
SCLN's Price-to-Operating-Cash-Flow is ranked higher than
53% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. SCLN: 16.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SCLN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.78  Med: 15.33 Max: 218.1
Current: 16.52
3.78
218.1
EV-to-EBIT 9.56
SCLN's EV-to-EBIT is ranked higher than
84% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. SCLN: 9.56 )
Ranked among companies with meaningful EV-to-EBIT only.
SCLN' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.8  Med: 8.5 Max: 202.4
Current: 9.56
-19.8
202.4
EV-to-EBITDA 9.35
SCLN's EV-to-EBITDA is ranked higher than
79% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. SCLN: 9.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCLN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.8  Med: 8 Max: 51.1
Current: 9.35
-22.8
51.1
EV-to-Revenue 2.47
SCLN's EV-to-Revenue is ranked higher than
58% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. SCLN: 2.47 )
Ranked among companies with meaningful EV-to-Revenue only.
SCLN' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 1.8 Max: 3.8
Current: 2.47
0.2
3.8
PEG Ratio 0.84
SCLN's PEG Ratio is ranked higher than
79% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.89 vs. SCLN: 0.84 )
Ranked among companies with meaningful PEG Ratio only.
SCLN' s PEG Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.77 Max: 3.2
Current: 0.84
0.84
3.2
Shiller PE Ratio 30.38
SCLN's Shiller PE Ratio is ranked higher than
60% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. SCLN: 30.38 )
Ranked among companies with meaningful Shiller PE Ratio only.
SCLN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 26.08  Med: 50.43 Max: 590
Current: 30.38
26.08
590
Current Ratio 8.36
SCLN's Current Ratio is ranked higher than
87% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. SCLN: 8.36 )
Ranked among companies with meaningful Current Ratio only.
SCLN' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 6.29 Max: 28.28
Current: 8.36
0.57
28.28
Quick Ratio 7.56
SCLN's Quick Ratio is ranked higher than
87% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. SCLN: 7.56 )
Ranked among companies with meaningful Quick Ratio only.
SCLN' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 5.75 Max: 28.28
Current: 7.56
0.57
28.28
Days Inventory 248.59
SCLN's Days Inventory is ranked lower than
90% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. SCLN: 248.59 )
Ranked among companies with meaningful Days Inventory only.
SCLN' s Days Inventory Range Over the Past 10 Years
Min: 171.31  Med: 212.93 Max: 265.07
Current: 248.59
171.31
265.07
Days Sales Outstanding 101.85
SCLN's Days Sales Outstanding is ranked lower than
70% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. SCLN: 101.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCLN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 80.45  Med: 106.88 Max: 131.53
Current: 101.85
80.45
131.53
Days Payable 111.21
SCLN's Days Payable is ranked higher than
74% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. SCLN: 111.21 )
Ranked among companies with meaningful Days Payable only.
SCLN' s Days Payable Range Over the Past 10 Years
Min: 58.1  Med: 94.63 Max: 159.4
Current: 111.21
58.1
159.4

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.70
SCLN's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. SCLN: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SCLN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -99.2  Med: -4.25 Max: 4.8
Current: 0.7
-99.2
4.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.50
SCLN's Price-to-Net-Cash is ranked higher than
77% of the 234 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.00 vs. SCLN: 4.50 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SCLN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.06  Med: 6.25 Max: 713
Current: 4.5
2.06
713
Price-to-Net-Current-Asset-Value 2.87
SCLN's Price-to-Net-Current-Asset-Value is ranked higher than
82% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. SCLN: 2.87 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SCLN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.93  Med: 3.84 Max: 53.57
Current: 2.87
0.93
53.57
Price-to-Tangible-Book 2.67
SCLN's Price-to-Tangible-Book is ranked higher than
61% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. SCLN: 2.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SCLN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 3.4 Max: 18.21
Current: 2.67
0.84
18.21
Price-to-Intrinsic-Value-Projected-FCF 1.20
SCLN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. SCLN: 1.20 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SCLN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.19 Max: 6.05
Current: 1.2
0.69
6.05
Price-to-Median-PS-Value 1.42
SCLN's Price-to-Median-PS-Value is ranked lower than
75% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. SCLN: 1.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SCLN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 2.18 Max: 769
Current: 1.42
0.26
769
Price-to-Graham-Number 1.27
SCLN's Price-to-Graham-Number is ranked higher than
72% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.97 vs. SCLN: 1.27 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SCLN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.68  Med: 1.51 Max: 4.46
Current: 1.27
0.68
4.46
Earnings Yield (Greenblatt) % 10.46
SCLN's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. SCLN: 10.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SCLN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -77.7  Med: 8.6 Max: 489.3
Current: 10.46
-77.7
489.3

More Statistics

Revenue (TTM) (Mil) $172.02
EPS (TTM) $ 0.82
Beta1.26
Short Percentage of Float1.26%
52-Week Range $8.55 - 11.43
Shares Outstanding (Mil)52.19

Analyst Estimate

Dec19 Dec20
Revenue (Mil $) 194 202
EPS ($) 1.33 1.42
EPS without NRI ($) 1.33 1.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}